NanoViricides, Inc. (NYSE American: NNVC) announced continued progress in advancing its broad-spectrum antiviral drug candidate NV-387 toward a Phase II clinical trial for the current Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo (DRC). The proposed trial has been approved by the DRC Pillar Committee, with preparations underway for ethics and regulatory submissions, the company stated.
NV-387 is the only orally administered Ebola treatment candidate currently under consideration for clinical trials, offering potential advantages in resource-limited outbreak settings where infusion-based therapies are difficult to deploy. The company highlighted the continued expansion of the outbreak, citing 1,561 confirmed cases and 506 deaths in the DRC as of July 6, while emphasizing that no approved treatment or vaccine currently exists for the Bundibugyo strain.
NanoViricides believes NV-387's broad-spectrum antiviral mechanism could provide activity against multiple ebolavirus strains. The same oral gummies formulation has already received approval from DRC regulators for a Phase II trial in Mpox, with product shipped to the country for that study.
The company's lead drug candidate, NV-387, is also being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and Measles. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
This development is significant because the Bundibugyo strain of Ebola has no approved treatment or vaccine, and the outbreak in the DRC continues to grow. An oral treatment could be a game-changer in outbreak settings where intravenous therapies are challenging to administer. The potential impact extends beyond Ebola, as NV-387's broad-spectrum mechanism could address multiple viral threats.
For more information, view the full press release at https://ibn.fm/LaNwF.
About NanoViricides: NanoViricides, Inc. is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug. The company's platform technology is based on the TheraCour nanomedicine technology. For more details, visit www.nanoviricides.com.
